Showing results (291-300 of 652) with videos related to
Sort By:
Pageof 66
Science Advances|December 8, 2018
Applying ecological resistance and resilience to dissect bacterial antibiotic responsesHannah R Meredith, Virgile Andreani, Helena R Ma, et al.Infection Control and Hospital Epidemiology|April 14, 2023
Disparities in central line-associated bloodstream infection and catheter-associated urinary tract infection rates: An exploratory analysisErin B Gettler, Ibukunoluwa C Kalu, Nwora L Okeke, et al.Antimicrobial Stewardship & Healthcare Epidemiology : ASHE|April 10, 2023
Using the COM-B model to identify barriers to and facilitators of evidence-based nurse urine-culture practicesSonali D Advani, Ali Winters, Nicholas A Turner, et al.Infection Control and Hospital Epidemiology|July 14, 2025
Epidemiologic validation of the National Healthcare Safety Network's updated Clostridioides difficile test method definitionNicholas A Turner, Barry Shelton, Becky A Smith, et al.American Journal of Infection Control|March 4, 2014
Effectiveness and cost of implementing an active surveillance screening policy for Acinetobacter baumannii: a Monte Carlo simulation modelJoseph R Coyle, Keith S Kaye, Thomas Taylor, et al.American Journal of Infection Control|April 4, 2015
Burden of Clostridium difficile infection on hospital readmissions and its potential impact under the Hospital Readmission Reduction ProgramTeena Chopra, Anupama Neelakanta, Carolyn Dombecki, et al.Antimicrobial Agents and Chemotherapy|March 30, 2006
Clinical and economic impact of bacteremia with extended- spectrum-beta-lactamase-producing EnterobacteriaceaeMitchell J Schwaber, Shiri Navon-Venezia, Keith S Kaye, et al.Antibiotics (Basel, Switzerland)|March 29, 2023
Challenges and Opportunities in Antimicrobial Stewardship among Hematopoietic Stem Cell Transplant and Oncology PatientsAnjali Majumdar, Mansi R Shah, Jiyeon J Park, et al.Antimicrobial Agents and Chemotherapy|February 19, 2002
Risk factors for piperacillin-tazobactam-resistant Pseudomonas aeruginosa among hospitalized patientsAnthony D Harris, Eli Perencevich, Mary-Claire Roghmann, et al.Journal of Chemotherapy (Florence, Italy)|March 31, 2015
Ceftaroline fosamil as first-line versus second-line treatment for acute bacterial skin and skin structure infections (ABSSSI) or community-acquired bacterial pneumonia (CABP)David J Guervil, Keith S Kaye, Ali Hassoun, et al.Pageof 66